Skip to content

Pending tax disputes and civil case add risk to Symbiotech’s IPO

By News Analysis India · · 1 min read

According to the filing, Symbiotech Pharmalab faces a suite of legal challenges spread across various courts and regulatory bodies. Two criminal cases and eleven tax matters involving directors total Rs 41.2 lakh, while a criminal case against a subsidiary brings another Rs 36.7 lakh. In addition, a key civil case linked to the promoter group remains unresolved. The company classifies these proceedings under its materiality policy, stating that the disclosed amounts represent the full extent of identifiable and quantifiable exposure.